This review presents only those contributions that have progressed fro
m the bench to the clinic using murine monoclonal antibodies coupled c
hemically to toxins, their subunits or ribosome-inactivating proteins.
The rationale and progress in the development, characterization, prec
linical testing and clinical trials are discussed.